Silvina Nordenstohl’s Post

⭐ Improve your diagnostic recognition of skin tumors ⭐ Embark on a journey to refine your dermoscopy skills with YouDermoscopy, the ultimate companion for dermatology enthusiasts. 🔍 Discover Intuitive Training: Step into a world of tiered training quizzes designed to elevate your diagnostic prowess. Whether you're a beginner or a seasoned pro, YouDermoscopy offers a structured approach to sharpening your abilities. 🌍 Engage Globally with Play Live: Join a vibrant community of dermatologists worldwide in Play Live sessions. Ask your colleagues for their opinion on your dermoscopic cases, exchange insights, and learn from diverse perspectives. It's a unique opportunity to expand your knowledge and connect with like-minded professionals. 🔬 Contribute to Cutting-Edge Research: With our Bonus Research feature, you become part of the forefront of dermoscopy innovation. Share your experiences and expertise anonymously, contributing to scientific advancements in the field. Together, we're shaping the future of dermoscopy. 💡 Experience Innovation, Free of Charge: Experience the sleek design and user-friendly interface of YouDermoscopy. Best of all, it's completely free! Dive into over 10,000 lesions, explore visually captivating content, and immerse yourself in the world of dermoscopy without any cost barriers. ⏱️ Rise to the Challenge: Compete against your peers, climb the leaderboard, and establish yourself as a dermoscopy expert. Every session is an opportunity to refine your skills and showcase your expertise. 🤝 Prestigious Collaborations: Developed by Meeter in collaboration with Prof. Giuseppe Argenziano and the Skin Cancer Unit of Università della Campania "Vanvitelli", with the exclusive contribution of Eau Thermale Avène. Ready to embark on this transformative journey? Visit the website and download the app https://lnkd.in/eiB9ANE6 to get started today. YouDermoscopy: Where passion meets innovation, empowering dermatological skills. #youdermoscopy #dermoscopytraining #skincancer #dermoscopyapp

Today we celebrate LEO Pharma's 115th anniversary, which is why internally today is known simply as LEO Pharma Day. We've been marking this important day since 1958. In addition to festive events and team activities, we will use LEO Pharma Day 2023 to ask: What have we gained and learned from 115 years in healthcare? And how do the learnings of past achievements give us an edge and a basis for ensuring success in the future? We're almost at the end of 2023 and it has been an incredible year for LEO Pharma! We are delivering results, generating momentum and operating in line with a corporate strategy that is crucial not just for the growth and financial sustainability of LEO Pharma. Equally, it is instrumental to helping our patients. Because at the end of the day, LEO Pharma is committed to precisely this: to continue making a fundamental difference for those who need us most in medical dermatology. #DermatologyBeyondTheSkin #LEOPharma

Diagnoses in dermatology and dermatopathology are not always made by first impression. The awareness and use of advanced tools like AI based image analysis and molecular diagnostics are rapidly increasing. Last Friday, I co-represented Dermagnostix at our official launch event of PsorX-LabDisk at the annual meeting of the #ADH Göttingen and the feedback and interest we received for our molecular diagnostics innovation was truly amazing and encouraging. A huge thanks to the organizers for focusing on molecular diagnostics and offering a stage for innovation! Just the day after, I was invited to speak about immunopathways and IL-23 at Pso+ conference organized by Janssen where I took the chance to highlight the white spots on the dermatology map that keep driving research on diagnostics, prognostics and theranostics. Balancing my roles as Managing Director and founder of Dermagnostix, and as a researcher in translational dermatoimmunology, is challenging. It involves a wide range of tasks, from investor communications to drafting scientific publications. While focusing on one path might reduce complexity, playing this dual role at the intersection of research and business is both exciting and rewarding. What do you think? #Leadership #Entrepreneurship #Research #Dermatology #Innovation #TranslationalResearch #Dermagnostix  

Exciting news from #Galderma! The results of the phase III trial of their investigational drug for prurigo nodularis have been published in the New England Journal of Medicine. Galderma's scientific method has proven to be robust, and they're hopeful that this brings us one step closer to finding relief from itch for patients with Prurigo Nodularis. Learn more about the trial by reading the press release or the New England Journal of Medicine website. #Galderma #PrurigoNodularis #AdvancingDermatology #Innovation

➡ 𝗝𝗼𝗶𝗻 𝗼𝘂𝗿 𝘂𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝘄𝗲𝗯𝗶𝗻𝗮𝗿! Explore advances in deep-tissue therapeutic monitoring in our webinar, "𝗢𝗽𝘁𝗼𝗮𝗰𝗼𝘂𝘀𝘁𝗶𝗰 𝗶𝗺𝗮𝗴𝗶𝗻𝗴 𝗳𝗼𝗿 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴." Our speakers, Dr. Sara Di Giulio, Dr. Hailong He, and Dr. Dinish U. S, will present their respective research on non-invasive optoacoustic imaging biomarkers with ultra-broadband raster-scan optoacoustic mesoscopy (#RSOM) – an innovative imaging technology that offers advanced optical imaging of the skin with assessment of endothelial function. RSOM has been successfully introduced into clinical diagnostics in the field of dermatology. This one-hour session will delve into the validation of critical biomarkers, with a Q&A session to facilitate professional discourse. 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗵𝗲𝗿𝗲: https://lnkd.in/gad3s-dZ Presented in partnership with the EU-funded Horizon2020 project WINTHER2020. Explore further: 𝗛𝗼𝗺𝗲𝗽𝗮𝗴𝗲: https://lnkd.in/enmKsB3v 𝗧𝘄𝗶𝘁𝘁𝗲𝗿 (𝗫): https://lnkd.in/dva_JkYy #optoacoustics #photoacoustics #molecularimaging #clinicalresearch

Diving into dermatology research with Dr. Robert Bissonnette and Dr. Kim Papp! 💡 📊 From Innovaderm and Probity Medical Research Inc., they tackled the key challenges in conducting vitiligo studies, the intricacies of early phase studies, and shared insights into alopecia areata (AA) studies 🔬 “[...] a shift in regulatory preferences has emerged: some authorities now advocate for single ascending dose (SAD) studies exclusively in healthy volunteers, while recommending that multiple ascending dose (MAD) studies be conducted directly in patients.” Robert Bissonnette, Innovaderm Research #dermatologyCRO #clinicalresearch #partnership #dermatalogyexperts __ Plongez dans la recherche dermatologique avec Dr Bissonnette et Dr Papp! 💡 📊 Suivez le lien pour accéder à l’entrevue complète (en anglais seulement)

We're doing a deep dive into holiday marketing strategies and getting a jump start on your 2024 marketing strategy. Join us Wednesday, October 25 and Thursday, October 26, for our members-only community calls with special guest Jennifer Church Kilkenny, aesthetic medical digital marketing specialist and owner of Total Social Solutions. 📅 Wednesday, October 25, 2023 12 pm PT / 1 pm MT/ 2 pm CT / 3 pm ET Developing Your Strategic Digital Marketing Plan for 2024 Join this APX Workshop for an interactive, supportive community, where you’ll glean insights from case studies, share perspectives with peers, and garner feedback from our expert guest presenter, to refine your marketing strategies. Whether you’re a seasoned marketing professional or an aesthetic practitioner seeking to establish your online presence, this workshop is sculpted to elevate your digital marketing presence in 2024. Let 2024 be the year where your digital stories engage and convert like never before. 📅 Thursday, October 26, 2023 - 12 pm PT / 1 pm MT/ 2 pm CT / 3 pm ET Innovative Holiday Marketing Tips During this call, we’ll continue what you learned during yesterday’s APX Workshop to provide some great practical and innovative marketing tips to elevate your practice's visibility and client engagement during the holidays. Learn how to: - Create a festive brand image - Create holiday packages that sell - Leverage social media and other online platforms - Incorporate loyalty and patient appreciation - Form strategic partnerships - Create a positive client experience ⭐ Bring your questions to ask during the open forum period. 👉 APX Platform Users: Join our APX Community group on Facebook to stay aware of upcoming community calls and receive instructions on how to access our community calls and workshops for APX members only. Ask your practice consultant for more info on how to access the group. 👉 Not an APX Platform User: Learn more about our platform and services when you visit our website at APXPlatform.com. #apxplatform #engagetechnologiesgroup #terrirossconsulting #totalsocialsolutions #aestheticmarketing #medicalaesthetics #plasticsurgery #dermatology #medicalspa #digitalmarketing #plasticsurgerymarketing #dermatologymarketing #medspamarketing #marketingstrategy

During DIAD-DIAL, where the world of dermatology converges- the pinnacle of precise diagnosis, and DIAD - DIAL - the path to effective treatments. Random question with creative team 😍 Here is DUBIMED family

Prurigo nodularis and atopic dermatitis manifest differently for patients, but they often have one thing in common: persistent and debilitating itch. Listen as some of dermatology’s leading voices, Shawn Kwatra, M.D., and Jonathan Silverberg M.D., PhD, MPH, discuss Galderma’s upcoming symposium this Saturday. Titled ‘Perspectives on Itch: Sharing Experiences and Understanding the Burden,’ it’s hosted in collaboration with the National Eczema Association. Together we’ll examine the impact of itch, with the patient perspective at the forefront.    #HCPsonly #AdvancingDermatology #AAD2024 

Today, we are excited to share topline results from two phase IIIb trials investigating RelabotulinumtoxinA for the treatment of glabellar lines (frown lines) and lateral canthal lines (crow’s feet). Both studies met their primary endpoints, demonstrating significant improvement, rapid onset of action, and long duration. Some patients reported improvement as early as day one in both trials, with at least a third of patients rating their frown lines as ‘improved’ or better through to month 12. These results demonstrate Galderma’s commitment to neuromodulator innovation and our focus on addressing real patient needs. RelabotulinumtoxinA is a highly-active, innovative, complex-free, and ready-to-use liquid botulinum toxin A with a proprietary strain, manufactured using a unique state-of-the-art process. We will continue to investigate RelabotulinumtoxinA globally as we expand our neuromodulator offering, as part of the market’s broadest Injectable Aesthetics portfolio. Read more: https://lnkd.in/d3-wvpQy   #AdvancingDermatology #SkinScienceByGalderma